구조모아 (StructureMoa)항암 chemical structure spider web
방문Hemogenyx Pharmaceuticals LLC
lymphodepleting chemotherapy(Hemogenyx Pharmaceuticals LLC)은 Non-Hodgkin Lymphoma 표적 치료제로, Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia. Phase 3 후기 임상 단계입니다. 선택한 코호트에서 보고된 효능: ORR 43.8% (ClinicalTrials.gov NCT02445248). 차별점: first-in-class autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma with progression after anti-pro.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Non-Hodgkin Lymphoma
Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer
Active
2026-09-02
Data Confidence · Low
Development Signal · Emerging
CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Mye
humanized anti-B cell maturation antigen (BCMA) CAR, in adults with relapsed or refractory multiple myeloma
first-in-class autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma with progression after anti-pro
CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia
cytokine release syndrome, and one had grade ≥3 immune effector cell-associated neurotoxicity syndrome
apoptosis, particularly in naïve and central memory CD8 + T cells, and simultaneously enhances regulatory T cells and tolero
biomarkers exist to predict toxicity risk, underscoring the need for further research
bypass ex vivo manufacturing and lymphodepletion, potentially simplifying and accelerating access to cellular therapy; prelimi
구조화 데이터
rated efficacy across additional preclinical tumor model
mouse
Pd
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Hemogenyx Pharmaceuticals LLC
lymphodepleting chemotherapy(Hemogenyx Pharmaceuticals LLC)은 Non-Hodgkin Lymphoma 표적 치료제로, Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia. Phase 3 후기 임상 단계입니다. 선택한 코호트에서 보고된 효능: ORR 43.8% (ClinicalTrials.gov NCT02445248). 차별점: first-in-class autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma with progression after anti-pro.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Non-Hodgkin Lymphoma
Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer
Active
2026-09-02
Data Confidence · Low
Development Signal · Emerging
CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Mye
humanized anti-B cell maturation antigen (BCMA) CAR, in adults with relapsed or refractory multiple myeloma
first-in-class autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma with progression after anti-pro
CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia
cytokine release syndrome, and one had grade ≥3 immune effector cell-associated neurotoxicity syndrome
apoptosis, particularly in naïve and central memory CD8 + T cells, and simultaneously enhances regulatory T cells and tolero
biomarkers exist to predict toxicity risk, underscoring the need for further research
bypass ex vivo manufacturing and lymphodepletion, potentially simplifying and accelerating access to cellular therapy; prelimi
구조화 데이터
rated efficacy across additional preclinical tumor model
mouse
Pd
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.